Cell and Gene Therapy Market Overview

The cell and gene therapy (CGT) market is revolutionizing modern medicine by offering potentially curative treatments for diseases once considered untreatable. These advanced therapies target the underlying cause of diseases at the genetic or cellular level, opening new horizons in the treatment of cancers, rare genetic disorders, and degenerative diseases.

CGT combines the ability of gene therapy to alter genetic instructions with the restorative capacity of cell therapy. With increasing approvals, innovation in delivery mechanisms, and supportive regulatory frameworks, the CGT market is witnessing unprecedented growth and investment.

Market Size, CAGR, and Forecast (as per EMR Data)

According to the Expert Market Research (EMR) report:

• Market Value in 2023: USD 17.81 billion

• Forecasted CAGR (2024–2032): 22.5%

• Expected Market Size by 2032: USD 110.74 billion

This remarkable growth trajectory reflects the rapid pace of R&D, rising clinical trial success rates, and increasing commercialization of therapies.

Market Segmentation

The market is segmented based on therapy type, indication, application, end-user, and region.

By Therapy Type

• Cell Therapy

• Gene Therapy

Both segments are vital, but gene therapy is expected to grow at a faster pace due to its transformative potential in treating rare diseases and certain cancers.

By Indication

• Oncology

• Neurology

• Cardiovascular Diseases

• Musculoskeletal Disorders

• Infectious Diseases

• Others

Oncology dominates the indication segment as CGT is increasingly used for blood cancers and solid tumors. Neurological disorders and genetic conditions also present large unmet needs.

By Application

• Commercial

• Clinical

The clinical application segment currently dominates due to the vast pipeline of cell and gene therapies under development. However, as more products receive regulatory approval, commercial applications are expected to rise significantly.

By End-User

• Hospitals and Clinics

• Academic and Research Institutions

• Biopharmaceutical and Biotechnology Companies

Hospitals and clinics form the largest end-user segment, given their role in therapy administration, while biopharma companies play a central role in CGT development and innovation.

By Region

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East and Africa

North America leads due to advanced research infrastructure, regulatory support from the FDA, and high healthcare expenditure. Meanwhile, Asia Pacific is emerging as a key region for clinical trials and manufacturing.

For more information about this report visit

Key Growth Drivers

Increasing Prevalence of Genetic and Chronic Disorders

The growing global burden of inherited diseases, cancer, and degenerative conditions is driving demand for more effective, targeted treatments like CGT.

Rising Investments in Research and Development

Governments, biopharma giants, and venture capitalists are heavily investing in CGT research, fueling innovation and clinical success rates.

Regulatory Support and Accelerated Approvals

Agencies like the FDA and EMA have established fast-track pathways, breakthrough designations, and advanced therapy medicinal product (ATMP) regulations to speed up CGT approvals.

Technological Advancements

Progress in viral vectors, CRISPR gene editing, and personalized cell therapies has improved therapy precision, efficiency, and scalability.

Strategic Partnerships and Collaborations

Collaborations between biotech companies, academic institutions, and contract manufacturing organizations (CMOs) are expanding R&D capabilities and commercial reach.

Market Challenges

High Cost of Therapies

CGTs are among the most expensive therapies in the world. Treatments like CAR-T cell therapy can cost upwards of USD 400,000, limiting patient access.

Manufacturing and Scalability Constraints

Producing CGTs is complex and time-consuming, often involving individualized manufacturing that poses logistical and quality control challenges.

Regulatory Complexity

Each therapy may require a unique regulatory approach, particularly in emerging markets where CGT-specific guidelines are still evolving.

Limited Infrastructure and Trained Workforce

Administering and monitoring CGT requires specialized facilities and professionals, often lacking in low- and middle-income countries.

Top Companies (Key Players)

As per the EMR report, the leading companies in the global cell and gene therapy market include:

• Novartis AG

• Gilead Sciences, Inc.

• F. Hoffmann-La Roche Ltd

• Bristol-Myers Squibb Company

• Pfizer Inc.

• Johnson & Johnson Services, Inc.

• Biogen Inc.

• Sarepta Therapeutics

• Orchard Therapeutics

• Bluebird Bio, Inc.

These companies are actively engaged in clinical trials, strategic acquisitions, and regulatory submissions to expand their CGT pipelines.

Recent Developments

• Novartis expanded access to its CAR-T therapy, Kymriah®, across several new indications and geographies.

• Gilead Sciences continued clinical advancement of Yescarta® for lymphoma and partnered with academic centers for early-stage research.

• Pfizer invested heavily in its gene therapy pipeline, focusing on rare diseases like hemophilia and Duchenne muscular dystrophy.

• Roche and Sarepta Therapeutics expanded their gene therapy collaborations to advance neuromuscular disease treatments.

FAQs for SEO (Answer-Focused for Featured Snippets)

What is the cell and gene therapy market size?

According to EMR, the global cell and gene therapy market was valued at USD 17.81 billion in 2023 and is expected to reach USD 110.74 billion by 2032.

What is driving the growth of the CGT market?

The market is driven by rising chronic diseases, genetic disorder prevalence, regulatory support, and R&D investments in innovative therapies.

Which companies are leading the CGT market?

Key players include Novartis, Gilead Sciences, Pfizer, Biogen, and Sarepta Therapeutics, known for their extensive pipelines and commercial therapies.

What diseases can cell and gene therapy treat?

CGT can treat oncological, neurological, cardiovascular, genetic, and infectious diseases, offering curative potential in many cases.

What are the major challenges in the CGT market?

Challenges include high therapy costs, complex manufacturing, regulatory barriers, and limited infrastructure in developing regions.

The cell and gene therapy market represents the future of personalized, precision medicine. With an impressive CAGR of 22.5% and a projected market value exceeding USD 110 billion by 2032, CGT is reshaping treatment paradigms for genetic disorders, cancer, and beyond.

Find More Blog:

CDMO Market growth

Surgical Site Infection (SSI) Drug Pipeline Analysis size

Transitional Cell Carcinoma Drug Pipeline Analysis trend